Top Tech Companies (2,068)
Don't see your company?
Create a company profile
Verve Therapeutics is a clinical-stage biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. In 2023, Verve was recognized as a "Best Places to Work" by the Boston Globe. Verve is headquartered in Boston, Massachusetts
.png)
Bioskryb is a venture-backed startup bringing new solutions for cellular heterogeneity, in both the research and clinical space studies, using a proprietary genome amplification system.
ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. The activation of the innate immune system is key to the development of immunological memory. Over the last two decades, our founder and Executive Chairman Dr. Patrick Soon-Shiong has investigated mechanisms to activate the immune system to attack tumors that can otherwise evade and escape the body’s defense mechanisms. After inventing the world’s first protein nanoparticle drug, Abraxane, Dr. Soon-Shiong turned his focus to the next generation of immunotherapies. ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious diseases. "At ImmunityBio, we envision a day when we no longer fear cancer but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease." -Dr. Patrick Soon-Shiong, Executive Chairman
Official account of the National Center for Biotechnology Information (NCBI) at the National Library of Medicine. NCBI serves as an international resource for the scientific research community - providing access to public databases and software tools for analyzing biological data, as well as performing research in computational biology. The NCBI was established in 1988 by an act of the United States Congress as division of the National Library of Medicine at the National Institutes of Health, with a mission to find new approaches to deal with the increasing volume and complexity of biological data in order to facilitate the understanding of genes and their role in health and disease. The NCBI is made up of multidisciplinary research and development teams composed of molecular biologists, biochemists, structural biologists, clinicians, mathematicians, and computer scientists who: Archive: Gather scientific and medical research data from around the globe • Serve as the largest repository of the world’s primary biological research data • Produce curated datasets to enhance the value and usability of the primary data Access: Develop systems for discovering and integrating scientific and medical data • Create search tools and data cross-referencing mechanisms • Display and enable download of information from the world's largest collection of biological data Advance: Promote understanding of processes that effect health and disease • Perform cutting-edge research in computational biology • Design and build algorithms, programs and systems for analysis of biological data • Provide support and training through a varied and vigorous outreach program
Interius is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next-generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania.
CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, CSL Plasma and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra
Accelerating biological understanding and discovery is more than a mission for 10x Genomics. It’s a commitment. Fueled by equal parts scientific vision and determined passion, we are enabling fundamental research across the life sciences by delivering rapid innovation that allows our customers to resolve complex biology—across the fields of oncology, immunology, neuroscience, and more. As we deliver powerful new methods for discovery, we create opportunities for scientists to address and reveal the true complexities of biology and disease. Already, our products have been adopted by researchers around the world, including 97 of the top 100 global research institutions and 19 of the top 20 global pharmaceutical companies, and have been cited in over 1,200 research papers on discoveries across the life sciences.
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.
Our mission is to identify, develop and deliver life-changing therapies to people living with rare disease. #InRareForLife Community Guidelines: https://travere.com/community-guidelines/
Gator Bio is a Silicon Valley biotech company with a mission to help biopharma scientists gain research insights faster. We fused engineering and science expertise to create novel analytical technologies that achieve better performance and more convenient solutions at a fraction of the cost of existing products. This is the biolayer interferometry solution you've been waiting for.
Putnam is a premier strategy consulting firm serving biopharmaceutical, diagnostics, medical device clients, and the private equity / venture capital community. For 30 years, we have offered objective, high impact strategic advice and analytical services, helping to support clients in crucial business decisions at all stages of the product and franchise lifecycle. Putnam is part of Inizio Advisory. Inizio is a strategic partner for health and life sciences with a full suite of medical, marketing, advisory and engagement services.
Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. We are focused on the development of proprietary therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. The promise of the CRISPR/Cas9 system is the driving force behind the creation of Intellia. Our founders have a shared belief that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. This technology offers the potential for us to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. It can bring new hope and cures to people who now have nowhere to turn for help. Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia has the right people, assets and ambitious vision needed to take full advantage of the CRISPR/Cas9 technology’s attributes – high potency, specificity, simplicity of use, broad applicability, and multifunctional programmability – and accelerate the advancement of curative products into the clinic. View our social media community guidelines at https://www.intelliatx.com/terms-and-conditions/
BlueRock Therapeutics is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ cell+gene platform harnesses the power of cells to create new medicines for neurology, cardiology, and immunology indications. BlueRock Therapeutics’ cell differentiation technology recapitulates the cell’s developmental biology to produce authentic cell therapies, which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock’s culture is defined by scientific innovation, the highest ethical standards and an urgency to bring transformative treatments to all who would benefit. The company strives to be a top employer of scientific talent, empowering every member of the team to make meaningful and lasting contributions to the burgeoning field of regenerative medicine. Become a BlueRocker! We are expanding our BlueRock team at all locations. Contact us via LinkedIn or our website to learn about rewarding career opportunities.
Azenta (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Azenta is headquartered in Chelmsford, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.
MedPharm is a world-leading contract provider of topical and transdermal product design and development services. Our delivery of robust and innovative research has commanded recognition from regulators and investors alike. We utilise our unique cost-effective performance testing models to mitigate risk and accelerate development times.
Here’s the deal. We’re all about helping biologics and gene therapy researchers break free from tools that just don’t cut it. Unleashing problem-tackling products that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it. We are located in Pleasanton, CA and can be found online at www.unchainedlabs.com.
Genesis Therapeutics is unifying AI and biotech to accelerate and optimize drug discovery. We pioneer novel deep learning and molecular simulation techniques to accelerate the development of new medicines. Genesis raised its $52M Series A from top tech + biotech investors, Andreessen Horowitz, Rock Springs, and T. Rowe Price. Story: https://techcrunch.com/2020/12/02/genesis-therapeutics-raises-52m-a-round-for-its-ai-focused-drug-discovery-mission/ We deploy our technology to accelerate a pipeline of several internal drug programs. Furthermore, Genesis has announced two significant, multi-target collaborations with Genentech and with Eli Lilly, the latter of which entailed a $20M upfront payment with a $670M total deal size. Now we are scaling the team and technology to support many more programs in parallel as well as increasingly difficult protein targets. We currently have a team (genesistherapeutics.ai/company.html#team) of about 35 people, split 50/50 between our ML / software team and our biochem team of veteran drug hunters in our own wetlab space. Our ML + software engineers are top-notch -- many graduates from MIT, UC Berkeley, Stanford. Previously worked at OpenAI, Google, Facebook, MemSQL, Jane Street, Dropbox, etc. We're recruiting pure ML research scientists + software engineers (no bio or chem experience expected) to further our core AI platform as well as scale our drug pipeline. Likewise, we have several openings in chemistry and biology to join our team of biotech + pharma veterans who are deploying the Genesis ML platform to discover novel drug candidates. Please apply on our website, or feel free to reach out via email directly: [email protected]
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.
Citrine Informatics is the award-winning materials informatics platform for data-driven materials and chemicals development. It won the 2017 World Materials Forum Start-up Challenge, the 2018 AI Breakthrough award as the "Best AI-based Solution for Manufacturing," and 2020-2021 Cleantech 100 honors. The Citrine Platform combines smart materials data infrastructure and AI, which accelerates development of cutting-edge materials, facilitates product portfolio optimization, and codifies research IP, enabling its reuse and preventing its loss. Citrine's customers include Panasonic, Michelin, LANXESS, and some of the biggest and most respected names in the materials and chemicals industry in Asia, North America, and Europe.
Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and delivery of immune-based therapies for patients around the world. Zenas is rapidly advancing a deep portfolio of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com
